A Randomized Trial Comparing Mitomycin C and Conjunctival Autograft After Excision of Primary Pterygium
References (27)
- et al.
Pingueculae and pterygia
Surv Ophthalmol
(1988) - et al.
Risk analysis in the development of pterygia
Ophthalmology
(1992) - et al.
Mitomycin eye drops as treatment for pterygium
Ophthalmology
(1988) - et al.
Conjunctival autograft transplantation for advanced and recurrent pterygium
Ophthalmology
(1985) A randomized trial of conjunctival autografting for pterygium in the tropics
Ophthalmology
(1989)- et al.
Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium
Am J Ophthalmol
(1988) - et al.
Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy [letter]
Am J Ophthalmol
(1991) - et al.
Serious complications of topical mitomycin-C after pterygium surgery
Ophthalmology
(1992) - et al.
Reply to Singh G: Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium [correspondence]
Am J Ophthalmol
(1989) - et al.
Reconstruction of the periocular mucous membrane by autologous conjunctival transplantation
Ophthalmology
(1982)
Conjunctival pterygia: mechanism of corneal topographic changes
Cornea
(1990)
Pterygium recurrence rate at the Princess Alexandra Hospital
Aust N Z J Ophthalmol
(1991)
Les pterygions recidivants: frequence et correction par autogreffe conjonctivale
Can J Ophthalmol
(1981)
Cited by (276)
SUTURED VERSUS SUTURELESS CONJUNCTIVAL AUTOGRAFT FOR PRIMARY PTERYGIUM
2023, Georgian Medical NewsAutologous fibrin glue versus sutures for conjunctival autograft in primary pterygium: a randomized clinical trial
2023, International Ophthalmology
This study was supported in part by a grant from the Autry Foundation, Los Angeles, California, and by an unrestricted grant from Research to Prevent Blindness, Inc., New York, New York. Dr. McDonnell is a Research to Prevent Blindness William and Mary Greve International Research Scholar.
No reprints are available
Copyright © 1995 Elsevier Inc. All rights reserved.